64287-11-2 Usage
Uses
Used in Pharmaceutical Industry:
4-N-Butylphenylhydrazine hydrochloride is used as an intermediate in the synthesis of pharmaceuticals for its potential anti-cancer properties. It is studied for its ability to exhibit anti-tumor activity, making it a promising candidate for the development of cancer treatments.
Used in Veterinary Products:
In the veterinary industry, 4-N-butylphenylhydrazine hydrochloride is used as a component in the production of veterinary products, potentially contributing to the treatment and prevention of diseases in animals.
Used in Cancer Research:
4-N-Butylphenylhydrazine hydrochloride is used as a research compound in cancer studies for its potential as an anti-cancer agent. It is investigated for its ability to modulate various oncological signaling pathways, which could lead to the development of novel therapeutic strategies against cancer.
Used in Anti-Inflammatory and Antioxidant Applications:
4-N-Butylphenylhydrazine hydrochloride is used in research for its anti-inflammatory properties and its capacity to reduce oxidative stress in the body. This makes it a candidate for the development of treatments targeting inflammation-related conditions and oxidative stress disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 64287-11-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,2,8 and 7 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 64287-11:
(7*6)+(6*4)+(5*2)+(4*8)+(3*7)+(2*1)+(1*1)=132
132 % 10 = 2
So 64287-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H16N2.ClH/c1-2-3-4-9-5-7-10(12-11)8-6-9;/h5-8,12H,2-4,11H2,1H3;1H
64287-11-2Relevant academic research and scientific papers
Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains
Bi, Fangchao,Song, Di,Qin, Yinhui,Liu, Xingbang,Teng, Yuetai,Zhang, Na,Zhang, Panpan,Zhang, Nan,Ma, Shutao
, p. 3179 - 3193 (2019/06/17)
The spread of infections caused by multidrug-resistant (MDR) pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA), has created a need for new antibiotics with novel mechanisms of action. The bacterial division protein FtsZ has been identified as a novel drug target that can be exploited clinically. As part of an ongoing effort to develop FtsZ-targeting antibacterial agents, we describe herein the design, synthesis and bioactivity of six series of novel 1,3,4-oxadiazol-2-one-containing, 1,2,4-triazol-3-one-containing and pyrazolin-5-one-containing benzamide derivatives. Among them, compound A14 was found to be the most potent antibacterial agent, much better than clinical drugs such as ciprofloxacin, linezolid and erythromycin against all the tested gram-positive strains, particularly methicillin-resistant, penicillin-resistant and clinical isolated S. aureus. Subsequent studies on biological activities and docking analyses proved that A14 functioned as an effective compound targeting FtsZ. Preliminary SAR indicated a general direction for further optimization of these novel analogues. Taken together, this research provides a promising chemotype for developing newer FtsZ-targeting bactericidal agents.
